Q2 Earnings Forecast for Omnicell Issued By Zacks Research

Omnicell, Inc. (NASDAQ:OMCL - Free Report) - Equities research analysts at Zacks Research increased their Q2 2025 earnings estimates for Omnicell in a research report issued on Tuesday, January 28th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.23 per share for the quarter, up from their prior forecast of $0.19. The consensus estimate for Omnicell's current full-year earnings is $0.94 per share. Zacks Research also issued estimates for Omnicell's Q2 2026 earnings at $0.32 EPS, Q4 2026 earnings at $0.21 EPS and FY2026 earnings at $1.04 EPS.

A number of other research analysts also recently weighed in on OMCL. StockNews.com downgraded Omnicell from a "buy" rating to a "hold" rating in a report on Tuesday, December 10th. JPMorgan Chase & Co. lifted their target price on Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a research note on Thursday, November 21st. Benchmark reissued a "buy" rating and issued a $62.00 price target on shares of Omnicell in a research report on Tuesday. Bank of America lowered their price objective on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research report on Monday, January 6th. Finally, Wells Fargo & Company cut their target price on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $52.33.

Omnicell Price Performance

NASDAQ OMCL traded up $0.49 on Friday, hitting $43.91. 187,899 shares of the stock were exchanged, compared to its average volume of 314,525. The company's 50-day moving average price is $44.64 and its two-hundred day moving average price is $43.10. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.74. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -112.59, a P/E/G ratio of 30.78 and a beta of 0.78.

Insider Buying and Selling at Omnicell

In other news, Director Mark W. Parrish sold 12,000 shares of the company's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the sale, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.64% of the company's stock.

Hedge Funds Weigh In On Omnicell

A number of institutional investors have recently modified their holdings of the company. Pier Capital LLC acquired a new stake in shares of Omnicell in the third quarter valued at about $5,859,000. Royce & Associates LP acquired a new stake in Omnicell in the 3rd quarter valued at approximately $811,000. Geode Capital Management LLC increased its position in Omnicell by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company's stock worth $48,176,000 after buying an additional 2,877 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in Omnicell by 750.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company's stock valued at $12,820,000 after purchasing an additional 259,463 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of Omnicell during the 3rd quarter worth about $753,000. Institutional investors own 97.70% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.